Brittany Louise Bychkovsky, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
BRCA2 Protein | 3 | 2023 | 794 | 1.270 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1149 | 1.130 |
Why?
|
Breast Neoplasms | 17 | 2023 | 20817 | 0.960 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1061 | 0.700 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 601 | 0.610 |
Why?
|
Tamoxifen | 1 | 2022 | 981 | 0.600 |
Why?
|
Genetic Predisposition to Disease | 5 | 2023 | 17449 | 0.520 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1353 | 0.470 |
Why?
|
Neoplasms | 8 | 2022 | 21672 | 0.470 |
Why?
|
Genes, BRCA2 | 3 | 2023 | 618 | 0.450 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2016 | 3474 | 0.420 |
Why?
|
Receptors, Progesterone | 1 | 2016 | 1097 | 0.410 |
Why?
|
Cervix Uteri | 1 | 2015 | 590 | 0.410 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 2186 | 0.400 |
Why?
|
Germ-Line Mutation | 4 | 2023 | 1787 | 0.390 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 491 | 0.340 |
Why?
|
DNA, Viral | 1 | 2015 | 2226 | 0.330 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2016 | 1509 | 0.310 |
Why?
|
Medical Oncology | 2 | 2021 | 2265 | 0.280 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4837 | 0.270 |
Why?
|
Neoadjuvant Therapy | 1 | 2016 | 2726 | 0.270 |
Why?
|
Population Surveillance | 1 | 2016 | 2616 | 0.260 |
Why?
|
Early Detection of Cancer | 5 | 2023 | 3086 | 0.260 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1587 | 0.230 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2019 | 0.230 |
Why?
|
Latin America | 4 | 2021 | 381 | 0.230 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6773 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9230 | 0.210 |
Why?
|
Female | 25 | 2023 | 380197 | 0.190 |
Why?
|
Blister | 1 | 2010 | 86 | 0.180 |
Why?
|
Chemoprevention | 1 | 2022 | 319 | 0.180 |
Why?
|
Germ Cells | 1 | 2023 | 631 | 0.170 |
Why?
|
Genetic Testing | 2 | 2022 | 3443 | 0.170 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 76 | 0.170 |
Why?
|
Breast Neoplasms, Male | 1 | 2020 | 210 | 0.170 |
Why?
|
Genetic Counseling | 1 | 2022 | 600 | 0.160 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 491 | 0.160 |
Why?
|
Humans | 31 | 2023 | 744220 | 0.150 |
Why?
|
Diphosphonates | 1 | 2011 | 624 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2016 | 162 | 0.140 |
Why?
|
Malawi | 1 | 2017 | 282 | 0.140 |
Why?
|
Acetic Acid | 1 | 2015 | 55 | 0.140 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4841 | 0.130 |
Why?
|
Biological Therapy | 1 | 2016 | 138 | 0.130 |
Why?
|
Medical History Taking | 1 | 2019 | 783 | 0.130 |
Why?
|
Indicators and Reagents | 1 | 2015 | 462 | 0.130 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2216 | 0.120 |
Why?
|
Bone Density Conservation Agents | 1 | 2011 | 773 | 0.120 |
Why?
|
Ultrasonography, Mammary | 1 | 2016 | 250 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13668 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1143 | 0.120 |
Why?
|
Neoplasm Staging | 3 | 2020 | 11007 | 0.120 |
Why?
|
Selenoproteins | 1 | 2005 | 216 | 0.120 |
Why?
|
Selenium | 1 | 2005 | 405 | 0.110 |
Why?
|
Genes, BRCA1 | 1 | 2016 | 781 | 0.110 |
Why?
|
Vaginal Smears | 1 | 2015 | 511 | 0.110 |
Why?
|
Osteoporosis | 1 | 2011 | 1580 | 0.100 |
Why?
|
Mammography | 3 | 2023 | 2477 | 0.100 |
Why?
|
Receptor, erbB-2 | 2 | 2023 | 2416 | 0.100 |
Why?
|
Health Planning | 1 | 2013 | 238 | 0.100 |
Why?
|
Alleles | 1 | 2022 | 6938 | 0.100 |
Why?
|
Positron-Emission Tomography | 2 | 2016 | 6274 | 0.090 |
Why?
|
Male | 8 | 2022 | 350027 | 0.090 |
Why?
|
National Health Programs | 1 | 2013 | 445 | 0.090 |
Why?
|
Papillomaviridae | 1 | 2015 | 1119 | 0.090 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2525 | 0.090 |
Why?
|
Referral and Consultation | 2 | 2023 | 3528 | 0.080 |
Why?
|
Caribbean Region | 2 | 2021 | 194 | 0.080 |
Why?
|
Middle Aged | 9 | 2021 | 213367 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2019 | 2708 | 0.080 |
Why?
|
Patient Preference | 1 | 2014 | 887 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9685 | 0.070 |
Why?
|
Mannich Bases | 1 | 2005 | 3 | 0.070 |
Why?
|
Retrospective Studies | 3 | 2022 | 77426 | 0.070 |
Why?
|
NADH, NADPH Oxidoreductases | 1 | 2005 | 93 | 0.070 |
Why?
|
Antiprotozoal Agents | 1 | 2005 | 86 | 0.070 |
Why?
|
Aged | 9 | 2023 | 163253 | 0.060 |
Why?
|
Phenotype | 1 | 2022 | 16365 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15226 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9275 | 0.060 |
Why?
|
Ketones | 1 | 2005 | 188 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 9960 | 0.060 |
Why?
|
Immunotherapy | 1 | 2020 | 4440 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5102 | 0.060 |
Why?
|
Adult | 7 | 2020 | 214035 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 941 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39045 | 0.060 |
Why?
|
Hospitals | 1 | 2017 | 3952 | 0.060 |
Why?
|
Insurance, Health | 1 | 2015 | 2494 | 0.060 |
Why?
|
Health Services Accessibility | 3 | 2021 | 5138 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 4044 | 0.050 |
Why?
|
Incidence | 2 | 2019 | 20945 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2021 | 5319 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13409 | 0.050 |
Why?
|
Lactation | 1 | 2023 | 412 | 0.050 |
Why?
|
Phthalazines | 1 | 2023 | 363 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3023 | 0.050 |
Why?
|
Healthcare Disparities | 2 | 2014 | 3158 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2020 | 57768 | 0.050 |
Why?
|
Decision Making | 1 | 2014 | 3888 | 0.040 |
Why?
|
Cohort Studies | 2 | 2020 | 40559 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2010 | 175 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7281 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 72280 | 0.040 |
Why?
|
Mutation | 2 | 2020 | 29784 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 840 | 0.040 |
Why?
|
Young Adult | 3 | 2020 | 56436 | 0.040 |
Why?
|
Cocaine-Related Disorders | 1 | 2010 | 460 | 0.040 |
Why?
|
Genomics | 2 | 2023 | 5722 | 0.030 |
Why?
|
United States | 2 | 2023 | 69867 | 0.030 |
Why?
|
Breast Feeding | 1 | 2023 | 1339 | 0.030 |
Why?
|
Prospective Studies | 1 | 2019 | 53280 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1969 | 0.030 |
Why?
|
Medicine, Chinese Traditional | 1 | 2014 | 71 | 0.030 |
Why?
|
West Indies | 1 | 2013 | 34 | 0.030 |
Why?
|
Economic Development | 1 | 2014 | 69 | 0.030 |
Why?
|
Russia | 1 | 2014 | 408 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20123 | 0.030 |
Why?
|
Urban Health Services | 1 | 2014 | 179 | 0.030 |
Why?
|
Environmental Pollution | 1 | 2014 | 118 | 0.030 |
Why?
|
Developed Countries | 1 | 2015 | 437 | 0.030 |
Why?
|
Cultural Characteristics | 1 | 2014 | 262 | 0.030 |
Why?
|
Cost of Illness | 1 | 2021 | 1859 | 0.030 |
Why?
|
Rural Health Services | 1 | 2014 | 379 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6535 | 0.020 |
Why?
|
Risk Assessment | 2 | 2023 | 23337 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29050 | 0.020 |
Why?
|
Models, Organizational | 1 | 2013 | 574 | 0.020 |
Why?
|
Health Services | 1 | 2014 | 758 | 0.020 |
Why?
|
China | 1 | 2014 | 2247 | 0.020 |
Why?
|
Biopsy | 1 | 2010 | 6757 | 0.020 |
Why?
|
Social Stigma | 1 | 2014 | 701 | 0.020 |
Why?
|
Brazil | 1 | 2012 | 1270 | 0.020 |
Why?
|
India | 1 | 2014 | 2199 | 0.020 |
Why?
|
Trypanosoma brucei rhodesiense | 1 | 2005 | 12 | 0.020 |
Why?
|
Glutathione Reductase | 1 | 2005 | 25 | 0.020 |
Why?
|
Drug Storage | 1 | 2005 | 51 | 0.020 |
Why?
|
Thioredoxin-Disulfide Reductase | 1 | 2005 | 45 | 0.020 |
Why?
|
Trypanocidal Agents | 1 | 2005 | 38 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12781 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6566 | 0.020 |
Why?
|
Leishmania donovani | 1 | 2005 | 65 | 0.020 |
Why?
|
Radiotherapy | 1 | 2012 | 1525 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 12961 | 0.020 |
Why?
|
Dimethyl Sulfoxide | 1 | 2005 | 249 | 0.020 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 276 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 503 | 0.010 |
Why?
|
Trypanosoma cruzi | 1 | 2005 | 198 | 0.010 |
Why?
|
Health Care Reform | 1 | 2013 | 1261 | 0.010 |
Why?
|
Mastectomy | 1 | 2012 | 1793 | 0.010 |
Why?
|
Alcoholism | 1 | 2014 | 1906 | 0.010 |
Why?
|
Glutathione | 1 | 2005 | 588 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2012 | 2050 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 1574 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 29142 | 0.010 |
Why?
|
Adolescent | 2 | 2020 | 85759 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2012 | 63119 | 0.010 |
Why?
|
Antimalarials | 1 | 2005 | 907 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 7784 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3746 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 8986 | 0.010 |
Why?
|
Mass Screening | 1 | 2012 | 5252 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15070 | 0.010 |
Why?
|
Plasmodium falciparum | 1 | 2005 | 1732 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2005 | 3760 | 0.010 |
Why?
|
Animals | 2 | 2005 | 168788 | 0.010 |
Why?
|